Catalyst

Slingshot members are tracking this event:

Anavex (AVXL) Announces Two-Year Extension to Phase 2a Dose-Response Analysis of 2-73 in Alzheimer's Disease

Source Link:
http://www.anavex.com/?news=anavex-announces-two-year-clinical-extension-study-of-anavex-2-73-and-presents-phase-2a-dose-response-analysis-at-aat-conference

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AVXL
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 10, 2016
Related Projects Image
Related Keywords Two-year Extension, Phase 2a Dose-response Analysis, 2-73, Alzheimer's Disease
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.